Peg Brivanlou is a Partner in King & Spalding’s Intellectual Property, Patent, Trademark and Copyright Litigation practice, specializing in patent prosecution, client counseling, due diligence and patent litigation. Peg represents clients in the biotechnology and pharmaceutical industries, and investment funds in a variety of intellectual property matters.
With a focus on biologics and small molecule therapeutics, Peg counsels clients regarding immunotherapeutics, cell-based assays and therapies, genomics, bioinformatics, vaccines and small molecule pharmaceuticals. She is experienced in developing patent portfolios, particularly relating to biologics, antibody therapeutics and diagnostics. She also conducts patent invalidity, freedom-to-operate analyses and pre-litigation investigations, including for pre-Hatch-Waxman litigation.
In addition, Peg represents clients on the intellectual property aspects of a wide range of transactions, from technology transfer and out-licensing to multi-million-dollar asset purchases and financings. She conducts due diligence, and negotiates licensing and purchase agreements as well as disclosure documents in connection with public and private financings.
Peg is listed as an IP Star in the 2018/2019 rankings of Managing Intellectual Property.